ARCH Venture Partners

Tracked participation in 2 Atlas companies, with 1 explicitly attributed lead.

2portfolio companies

3round participations

1lead positions

$1Bled round total

Conviction

Most recent leads

The latest rounds this investor is sourced as leading, newest first.

Apr 2024Xaira TherapeuticsSeries A (stealth launch / incubated by co-leads)$1B

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

XTXaira Therapeutics—Apr 2024 → Apr 20241 round1 led—

GGenerate:BiomedicinesScienceGenerate:Biomedicines (NASDAQ: GENB) is a clinical-stage generative biology company building protein therapeutics by…$1BraisedRecent roundsInitial Public Offering (IPO) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary (Series B investor), ADIA (wholly-owned subsidiary) +14Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary, Abu Dhabi Investment Authority (ADIA) subsidiary +9Generate:Biomedicines—Nov 2021 → Sep 20232 roundsParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Apr 24, 2024XTXaira TherapeuticsSeries A (stealth launch / incubated by co-leads)$1B—Lead

Source ↗

Sep 14, 2023GGenerate:BiomedicinesScienceGenerate:Biomedicines (NASDAQ: GENB) is a clinical-stage generative biology company building protein therapeutics by…$1BraisedRecent roundsInitial Public Offering (IPO) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary (Series B investor), ADIA (wholly-owned subsidiary) +14Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary, Abu Dhabi Investment Authority (ADIA) subsidiary +9Generate:BiomedicinesSeries C$273M—Participant

Source ↗

Nov 18, 2021GGenerate:BiomedicinesScienceGenerate:Biomedicines (NASDAQ: GENB) is a clinical-stage generative biology company building protein therapeutics by…$1BraisedRecent roundsInitial Public Offering (IPO) · Feb 2026$400M · Cantor Fitzgerald & Co., Goldman Sachs & Co. LLC +3Series C · Sep 2023$273M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary (Series B investor), ADIA (wholly-owned subsidiary) +14Series B · Nov 2021$370M · Abu Dhabi Investment Authority (ADIA) — wholly-owned subsidiary, Abu Dhabi Investment Authority (ADIA) subsidiary +9Generate:BiomedicinesSeries B$370M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Apr 24, 2024XTXaira TherapeuticsSeries A (stealth launch / incubated by co-leads)$1B—Lead

Source ↗